Cargando…

Preliminary Safety and Tolerability of a Novel Subcutaneous Intrathecal Catheter System for Repeated Outpatient Dosing of Nusinersen to Children and Adults With Spinal Muscular Atrophy

BACKGROUND: Many patients with spinal muscular atrophy (SMA) who might benefit from intrathecal antisense oligonucleotide (nusinersen) therapy have scoliosis or spinal fusion that precludes safe drug delivery. To circumvent spinal pathology, we designed a novel subcutaneous intrathecal catheter (SIC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strauss, Kevin A., Carson, Vincent J., Brigatti, Karlla W., Young, Millie, Robinson, Donna L., Hendrickson, Christine, Fox, Michael D., Reed, Robert M., Puffenberger, Erik G., Mackenzie, William, Miller, Freeman
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2018
Materias:	Neuromuscular
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6211782/ https://www.ncbi.nlm.nih.gov/pubmed/30134351 http://dx.doi.org/10.1097/BPO.0000000000001247

Ejemplares similares

Motor unit changes in children with symptomatic spinal muscular atrophy treated with nusinersen
por: Kariyawasam, Didu, et al.
Publicado: (2021)

Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients
por: Querin, Giorgia, et al.
Publicado: (2016)

Spinal muscular atrophy within Amish and Mennonite populations: Ancestral haplotypes and natural history
por: Carson, Vincent J., et al.
Publicado: (2018)

The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials
por: Ricotti, Valeria, et al.
Publicado: (2016)

Intrathecal Injections in Children With Spinal Muscular Atrophy: Nusinersen Clinical Trial Experience
por: Haché, Manon, et al.
Publicado: (2016)

Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy
por: Stolte, Benjamin, et al.
Publicado: (2018)

Cerebrospinal fluid characteristics of patients treated with intrathecal nusinersen for spinal muscular atrophy
por: Orbach, Rotem, et al.
Publicado: (2022)

Clinical features and a mutation with late onset of limb girdle muscular dystrophy 2B
por: Takahashi, Toshiaki, et al.
Publicado: (2013)

Validation of genetic modifiers for Duchenne muscular dystrophy: a multicentre study assessing SPP1 and LTBP4 variants
por: van den Bergen, Janneke C, et al.
Publicado: (2015)

Nusinersen for spinal muscular atrophy
por: Wurster, Claudia D., et al.
Publicado: (2018)

Intrathecal nusinersen administration in adult spinal muscular atrophy patients with complex spinal anatomy
por: Cordts, Isabell, et al.
Publicado: (2020)

The influence of tone on proximal femoral and acetabular geometry in neuromuscular hip displacement: A comparison of cerebral palsy and spinal muscular atrophy
por: Ulusaloglu, Armagan Can, et al.
Publicado: (2022)

Intrathecal administration of nusinersen for spinal muscular atrophy: report of three cases with severe spinal deformity
por: Nakao, Sayo, et al.
Publicado: (2020)

Radiation dose reduction for CT-guided intrathecal nusinersen administration in adult patients with spinal muscular atrophy
por: Cordts, Isabell, et al.
Publicado: (2020)

Nusinersen Treatment in Adults With Spinal Muscular Atrophy
por: Duong, Tina, et al.
Publicado: (2021)

Treatment with Ataluren for Duchene Muscular Dystrophy
por: Morkous, Sameh S.
Publicado: (2020)

Nusinersen as a Therapeutic Agent for Spinal Muscular Atrophy
por: Li, Qing
Publicado: (2020)

Nusinersen and Spinal Muscular Atrophies: Where are we in 2020?
por: Khadilkar, Satish V., et al.
Publicado: (2020)

Clinical Implication of Dosimetry of Computed Tomography- and Fluoroscopy-Guided Intrathecal Therapy With Nusinersen in Adult Patients With Spinal Muscular Atrophy
por: Kizina, Kathrin, et al.
Publicado: (2019)

Whole-genome sequencing and the clinician: a tale of two cities
por: Foley, A Reghan, et al.
Publicado: (2014)

Autosomal dominant eccentric core disease caused by a heterozygous mutation in the MYH7 gene
por: Romero, Norma B, et al.
Publicado: (2014)

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomised, double blind, placebo controlled, phase III study
por: Lauria, Giuseppe, et al.
Publicado: (2015)

Assessment of pulmonary function in amyotrophic lateral sclerosis: when can polygraphy help evaluate the need for non-invasive ventilation?
por: Prell, Tino, et al.
Publicado: (2016)

Imaging muscle as a potential biomarker of denervation in motor neuron disease
por: Jenkins, Thomas M, et al.
Publicado: (2018)

Intravenous immunoglobulin for maintenance treatment of chronic inflammatory demyelinating polyneuropathy: a multicentre, open-label, 52-week phase III trial
por: Kuwabara, Satoshi, et al.
Publicado: (2017)

Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2018)

Oral corticosteroid dosing regimen and long-term prognosis in generalised myasthenia gravis: a multicentre cross-sectional study in Japan
por: Imai, Tomihiro, et al.
Publicado: (2018)

Classifying Adverse Events Following Lower Limb Orthopaedic Surgery in Children With Cerebral Palsy: Reliability of the Modified Clavien-Dindo System
por: Zhou, Leena, et al.
Publicado: (2018)

Ultra-high-dose methylcobalamin in amyotrophic lateral sclerosis: a long-term phase II/III randomised controlled study
por: Kaji, Ryuji, et al.
Publicado: (2019)

Muscle MRI in patients with dysferlinopathy: pattern recognition and implications for clinical trials
por: Diaz-Manera, Jordi, et al.
Publicado: (2018)

Differentiating lower motor neuron syndromes
por: Garg, Nidhi, et al.
Publicado: (2017)

Untargeted metabolomics yields insight into ALS disease mechanisms
por: Goutman, Stephen A, et al.
Publicado: (2020)

Oral levosimendan in amyotrophic lateral sclerosis: a phase II multicentre, randomised, double-blind, placebo-controlled trial
por: Al-Chalabi, Ammar, et al.
Publicado: (2019)

Critical design considerations for time-to-event endpoints in amyotrophic lateral sclerosis clinical trials
por: van Eijk, Ruben P A, et al.
Publicado: (2019)

Myasthenia gravis AChR antibodies inhibit function of rapsyn-clustered AChRs
por: Cetin, Hakan, et al.
Publicado: (2020)

CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS
por: Capodivento, Giovanna, et al.
Publicado: (2021)

Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study
por: Verboon, Christine, et al.
Publicado: (2021)

IgG(1) pan-neurofascin antibodies identify a severe yet treatable neuropathy with a high mortality
por: Fehmi, Janev, et al.
Publicado: (2021)

Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF)
por: van Eijk, Ruben P A, et al.
Publicado: (2022)

Eculizumab versus rituximab in generalised myasthenia gravis
por: Nelke, Christopher, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nm6m9pnmt4mnf0hbe5ujrr9gmu